This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Raghavan, R. P Articles by Cummings, M. H Search for Related Content Social Bookmarking                   What's this?

Review: Aspirin and diabetes

Academic Department of Diabetes and Endocrinology, Diabetes Day Unit, Level 'C', Queen Alexandra Hospital, Cosham, Portsmouth, PO6 3LY, UK, rajeev.raghavan{at}porthosp.nhs.uk

David W Laight

School of Pharmacy & Biomedical Sciences, University of Portsmouth, 3rd Floor, St. Michael's Building, White Swan Road, Portsmouth, PO1 2DT, UK

Kenneth M Shaw

Academic Department of Diabetes and Endocrinology, Diabetes Day Unit, Level 'C', Queen Alexandra Hospital, Cosham, Portsmouth, PO6 3LY, UK

Michael H Cummings

Academic Department of Diabetes and Endocrinology, Diabetes Day Unit, Level 'C', Queen Alexandra Hospital, Cosham, Portsmouth, PO6 3LY, UK

Type 2 diabetes accounts for a large proportion of cardiovascular disease within the UK. Inflammation is increasingly seen as a core process (even touted as a causative factor) connecting the metabolic syndrome and cardiovascular disease. Inflammatory markers, adhesion molecules, transcription regulators such as PPAR-gamma and NF-kappa B are being recognised as key elements of the underlying pathological process. In particular the links between oxidative stress, metabolic syndrome components and a pro-inflammatory milieu are becoming increasingly recognised.

Salicylates have been used extensively for more than a hundred years but remain the subject of much research and scientific debate. Mechanisms of aspirin action, such as effects on endothelial function, oxidative stress, hyperglycaemia, inflammation, and mechanisms of aspirin resistance are being elucidated. With the advent of COX-2 selective inhibitors, the importance of the cyclo-oxygenase (COX-1 & COX-2 enzymes) pathways and the implications of more selective COX manipulation are being re-evaluated. There is no universal consensus on the use and dose of aspirin in diabetes. This review focuses upon the impact that aspirin may have to ameliorate the pathophysiology of diabetes and CVD.

Key Words: aspirin • inflammation • oxidative stress • cycloxygenase • endothelial function • NF ,metabolic syndrome • diabetes.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 74-82 (2006)
DOI: 10.1177/14746514060060020501


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?